Financial Information

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

March 2020 Regulatorisk

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Growth Market (”Nasdaq First North”). First day of trading on Nadaq First North is set to March 9, 2020.

February 21, Stayble communicated that that the Company’s new issue of SEK 35 million was subscribed to for approximately SEK 153 million (corresponding to a subscription rate of 436%). The Company will receive around 830 new shareholders, and issue 2 850 000 shares and 2 850 000 warrants of series TO1. The warrants could bring an additional amount of SEK 35 million to SEK 70 million before issue costs in December 2020. Terms and conditions for the warrants of series TO1 can be found in the prospectus published January 31, 2020.

The ticker for the Company’s shares on Nasdaq First North is STABL.
The ticker for the warrants of series TO1 on Nasdaq First North is STABL TO1.

Advisors
Mangold Fondkommission AB are financial advisors and Advokatfirman Schjødt are legal advisors.

 

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397

About Stayble Therapeutics AB Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and requires minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain. Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se
Release...Download PDF

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397